Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Therapeutic advances in neurological disorders

Leussink VI, Hartung HP, Kieseier BC, Stettner M.
PMID: 27366241
Ther Adv Neurol Disord. 2016 Jul;9(4):336-43. doi: 10.1177/1756285616641583. Epub 2016 Apr 06.

Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes, subcutaneous immunoglobulins (SCIgs) have represented a...

Cite
Leussink VI, Hartung HP, Kieseier BC, et al. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Ther Adv Neurol Disord. 2016;9(4):336-43doi: 10.1177/1756285616641583.
Leussink, V. I., Hartung, H. P., Kieseier, B. C., & Stettner, M. (2016). Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Therapeutic advances in neurological disorders, 9(4), 336-43. https://doi.org/10.1177/1756285616641583
Leussink, Verena I, et al. "Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies." Therapeutic advances in neurological disorders vol. 9,4 (2016): 336-43. doi: https://doi.org/10.1177/1756285616641583
Leussink VI, Hartung HP, Kieseier BC, Stettner M. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Ther Adv Neurol Disord. 2016 Jul;9(4):336-43. doi: 10.1177/1756285616641583. Epub 2016 Apr 06. PMID: 27366241; PMCID: PMC4916522.
Copy Download .nbib Format: NLM
Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?.

Neural regeneration research

Szepanowski F, Kleinschnitz C, Stettner M.
PMID: 31397340
Neural Regen Res. 2019 Dec;14(12):2079-2080. doi: 10.4103/1673-5374.262579.

No abstract available.

Cite
Szepanowski F, Kleinschnitz C, Stettner M. Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?. Neural Regen Res. 2019;14(12):2079-2080doi: 10.4103/1673-5374.262579.
Szepanowski, F., Kleinschnitz, C., & Stettner, M. (2019). Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?. Neural regeneration research, 14(12), 2079-2080. https://doi.org/10.4103/1673-5374.262579
Szepanowski, Fabian, et al. "Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?." Neural regeneration research vol. 14,12 (2019): 2079-2080. doi: https://doi.org/10.4103/1673-5374.262579
Szepanowski F, Kleinschnitz C, Stettner M. Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?. Neural Regen Res. 2019 Dec;14(12):2079-2080. doi: 10.4103/1673-5374.262579. PMID: 31397340; PMCID: PMC6788227.
Copy Download .nbib Format: NLM
Medical, Technical and Audiological Outcomes of Hearing Rehabilitation with the Bonebridge Transcutaneous Bone-Conduction Implant: A Single-Center Experience.

Journal of clinical medicine

Brkic FF, Riss D, Scheuba K, Arnoldner C, Gstöttner W, Baumgartner WD, Vyskocil E.
PMID: 31623414
J Clin Med. 2019 Oct 03;8(10). doi: 10.3390/jcm8101614.

Bone-conduction implants are a standard therapeutic option for patients with conductive, unilateral, or mixed hearing loss who either do not tolerate conventional hearing aids or can benefit from surgery. The aim of this study was to evaluate long-term medical...

Cite
Brkic FF, Riss D, Scheuba K, et al. Medical, Technical and Audiological Outcomes of Hearing Rehabilitation with the Bonebridge Transcutaneous Bone-Conduction Implant: A Single-Center Experience. J Clin Med. 2019;8(10)doi: 10.3390/jcm8101614.
Brkic, F. F., Riss, D., Scheuba, K., Arnoldner, C., Gstöttner, W., Baumgartner, W. D., & Vyskocil, E. (2019). Medical, Technical and Audiological Outcomes of Hearing Rehabilitation with the Bonebridge Transcutaneous Bone-Conduction Implant: A Single-Center Experience. Journal of clinical medicine, 8(10), . https://doi.org/10.3390/jcm8101614
Brkic, Faris F, et al. "Medical, Technical and Audiological Outcomes of Hearing Rehabilitation with the Bonebridge Transcutaneous Bone-Conduction Implant: A Single-Center Experience." Journal of clinical medicine vol. 8,10 (2019). doi: https://doi.org/10.3390/jcm8101614
Brkic FF, Riss D, Scheuba K, Arnoldner C, Gstöttner W, Baumgartner WD, Vyskocil E. Medical, Technical and Audiological Outcomes of Hearing Rehabilitation with the Bonebridge Transcutaneous Bone-Conduction Implant: A Single-Center Experience. J Clin Med. 2019 Oct 03;8(10). doi: 10.3390/jcm8101614. PMID: 31623414; PMCID: PMC6832994.
Copy Download .nbib Format: NLM
Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia.

Frontiers in neurology

Lee JI, Böcking T, Holle-Lee D, Malik RA, Kieseier BC, Hartung HP, Guthoff R, Kleinschnitz C, Stettner M.
PMID: 32793098
Front Neurol. 2020 Jul 24;11:661. doi: 10.3389/fneur.2020.00661. eCollection 2020.

No abstract available.

Cite
Lee JI, Böcking T, Holle-Lee D, et al. Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia. Front Neurol. 2020;11:661doi: 10.3389/fneur.2020.00661.
Lee, J. I., Böcking, T., Holle-Lee, D., Malik, R. A., Kieseier, B. C., Hartung, H. P., Guthoff, R., Kleinschnitz, C., & Stettner, M. (2020). Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia. Frontiers in neurology, 11661. https://doi.org/10.3389/fneur.2020.00661
Lee, John-Ih, et al. "Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia." Frontiers in neurology vol. 11 (2020): 661. doi: https://doi.org/10.3389/fneur.2020.00661
Lee JI, Böcking T, Holle-Lee D, Malik RA, Kieseier BC, Hartung HP, Guthoff R, Kleinschnitz C, Stettner M. Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia. Front Neurol. 2020 Jul 24;11:661. doi: 10.3389/fneur.2020.00661. eCollection 2020. PMID: 32793098; PMCID: PMC7393442.
Copy Download .nbib Format: NLM
Does the Use of the "Proseek.

Journal of clinical medicine

Perricos A, Wenzl R, Husslein H, Eiwegger T, Gstoettner M, Weinhaeusel A, Beikircher G, Kuessel L.
PMID: 32604857
J Clin Med. 2020 Jun 26;9(6). doi: 10.3390/jcm9062009.

Endometriosis appears to share certain cancer-related processes, such as cell attachment, invasion, proliferation and neovascularization, some of which can also be found in other healthy tissues. In order to better understand the altered milieu of the peritoneal cavity, while...

Cite
Perricos A, Wenzl R, Husslein H, et al. Does the Use of the "Proseek. J Clin Med. 2020;9(6)doi: 10.3390/jcm9062009.
Perricos, A., Wenzl, R., Husslein, H., Eiwegger, T., Gstoettner, M., Weinhaeusel, A., Beikircher, G., & Kuessel, L. (2020). Does the Use of the "Proseek. Journal of clinical medicine, 9(6), . https://doi.org/10.3390/jcm9062009
Perricos, Alexandra, et al. "Does the Use of the "Proseek." Journal of clinical medicine vol. 9,6 (2020). doi: https://doi.org/10.3390/jcm9062009
Perricos A, Wenzl R, Husslein H, Eiwegger T, Gstoettner M, Weinhaeusel A, Beikircher G, Kuessel L. Does the Use of the "Proseek. J Clin Med. 2020 Jun 26;9(6). doi: 10.3390/jcm9062009. PMID: 32604857; PMCID: PMC7355450.
Copy Download .nbib Format: NLM
LPA.

Journal of neuroinflammation

Szepanowski F, Winkelhausen M, Steubing RD, Mausberg AK, Kleinschnitz C, Stettner M.
PMID: 34920725
J Neuroinflammation. 2021 Dec 17;18(1):293. doi: 10.1186/s12974-021-02350-5.

BACKGROUND: Lysophosphatidic acid (LPA) is a pleiotropic lipid messenger that addresses at least six specific G-protein coupled receptors. Accumulating evidence indicates a significant involvement of LPA in immune cell regulation as well as Schwann cell physiology, with potential relevance...

Cite
Szepanowski F, Winkelhausen M, Steubing RD, et al. LPA. J Neuroinflammation. 2021;18(1):293doi: 10.1186/s12974-021-02350-5.
Szepanowski, F., Winkelhausen, M., Steubing, R. D., Mausberg, A. K., Kleinschnitz, C., & Stettner, M. (2021). LPA. Journal of neuroinflammation, 18(1), 293. https://doi.org/10.1186/s12974-021-02350-5
Szepanowski, Fabian, et al. "LPA." Journal of neuroinflammation vol. 18,1 (2021): 293. doi: https://doi.org/10.1186/s12974-021-02350-5
Szepanowski F, Winkelhausen M, Steubing RD, Mausberg AK, Kleinschnitz C, Stettner M. LPA. J Neuroinflammation. 2021 Dec 17;18(1):293. doi: 10.1186/s12974-021-02350-5. PMID: 34920725.
Copy Download .nbib Format: NLM
LPA.

Journal of neuroinflammation

Szepanowski F, Winkelhausen M, Steubing RD, Mausberg AK, Kleinschnitz C, Stettner M.
PMID: 34920725
J Neuroinflammation. 2021 Dec 17;18(1):293. doi: 10.1186/s12974-021-02350-5.

BACKGROUND: Lysophosphatidic acid (LPA) is a pleiotropic lipid messenger that addresses at least six specific G-protein coupled receptors. Accumulating evidence indicates a significant involvement of LPA in immune cell regulation as well as Schwann cell physiology, with potential relevance...

Cite
Szepanowski F, Winkelhausen M, Steubing RD, et al. LPA. J Neuroinflammation. 2021;18(1):293doi: 10.1186/s12974-021-02350-5.
Szepanowski, F., Winkelhausen, M., Steubing, R. D., Mausberg, A. K., Kleinschnitz, C., & Stettner, M. (2021). LPA. Journal of neuroinflammation, 18(1), 293. https://doi.org/10.1186/s12974-021-02350-5
Szepanowski, Fabian, et al. "LPA." Journal of neuroinflammation vol. 18,1 (2021): 293. doi: https://doi.org/10.1186/s12974-021-02350-5
Szepanowski F, Winkelhausen M, Steubing RD, Mausberg AK, Kleinschnitz C, Stettner M. LPA. J Neuroinflammation. 2021 Dec 17;18(1):293. doi: 10.1186/s12974-021-02350-5. PMID: 34920725.
Copy Download .nbib Format: NLM
Media on-demand: Continuous reconstitution of a chemically defined media directly from solids.

Biotechnology and bioengineering

Komuczki D, Dutra G, Gstöttner C, Dominguez-Vega E, Jungbauer A, Satzer P.
PMID: 33656168
Biotechnol Bioeng. 2021 Sep;118(9):3382-3394. doi: 10.1002/bit.27738. Epub 2021 Mar 25.

Chemically defined media are reconstituted batchwise and stored in hold tanks until use. To avoid large hold tanks and batchwise production of media, we developed continuous on-demand reconstitutions directly from solids consisting of a hopper and a screw conveyor...

Cite
Komuczki D, Dutra G, Gstöttner C, et al. Media on-demand: Continuous reconstitution of a chemically defined media directly from solids. Biotechnol Bioeng. 2021;118(9):3382-3394doi: 10.1002/bit.27738.
Komuczki, D., Dutra, G., Gstöttner, C., Dominguez-Vega, E., Jungbauer, A., & Satzer, P. (2021). Media on-demand: Continuous reconstitution of a chemically defined media directly from solids. Biotechnology and bioengineering, 118(9), 3382-3394. https://doi.org/10.1002/bit.27738
Komuczki, Daniel, et al. "Media on-demand: Continuous reconstitution of a chemically defined media directly from solids." Biotechnology and bioengineering vol. 118,9 (2021): 3382-3394. doi: https://doi.org/10.1002/bit.27738
Komuczki D, Dutra G, Gstöttner C, Dominguez-Vega E, Jungbauer A, Satzer P. Media on-demand: Continuous reconstitution of a chemically defined media directly from solids. Biotechnol Bioeng. 2021 Sep;118(9):3382-3394. doi: 10.1002/bit.27738. Epub 2021 Mar 25. PMID: 33656168; PMCID: PMC8451748.
Copy Download .nbib Format: NLM
Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report.

Therapeutic advances in neurological disorders

Asan L, Klebe S, Kleinschnitz C, Stettner M, Köhrmann M.
PMID: 34899988
Ther Adv Neurol Disord. 2021 Dec 08;14:17562864211062824. doi: 10.1177/17562864211062824. eCollection 2021.

We present a case of acute cerebellar ataxia and myoclonus with detected anti-GFAP-antibodies in a patient recently recovered from COVID-19. Main symptoms consisted of acute gait and limb ataxia and myoclonus. The patient improved considerably upon treatment with high-dose...

Cite
Asan L, Klebe S, Kleinschnitz C, et al. Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report. Ther Adv Neurol Disord. 2021;14:17562864211062824doi: 10.1177/17562864211062824.
Asan, L., Klebe, S., Kleinschnitz, C., Stettner, M., & Köhrmann, M. (2021). Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report. Therapeutic advances in neurological disorders, 1417562864211062824. https://doi.org/10.1177/17562864211062824
Asan, Livia, et al. "Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report." Therapeutic advances in neurological disorders vol. 14 (2021): 17562864211062824. doi: https://doi.org/10.1177/17562864211062824
Asan L, Klebe S, Kleinschnitz C, Stettner M, Köhrmann M. Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report. Ther Adv Neurol Disord. 2021 Dec 08;14:17562864211062824. doi: 10.1177/17562864211062824. eCollection 2021. PMID: 34899988; PMCID: PMC8664296.
Copy Download .nbib Format: NLM
Comment on Schäfer et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence": High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence.

Psychotherapy and psychosomatics

Dinse H, Speichert LJ, Schweda A, Witzke O, Konik M, Zettler M, Rohn H, Stettner M, Musche V, Weismüller B, Herchert K, Fink M, Moradian S, Teufel M, Skoda EM, Bäuerle A.
PMID: 34986479
Psychother Psychosom. 2022 Jan 05;1-3. doi: 10.1159/000520963. Epub 2022 Jan 05.

No abstract available.

Cite
Dinse H, Speichert LJ, Schweda A, et al. Comment on Schäfer et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence": High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence. Psychother Psychosom. 2022;1-3doi: 10.1159/000520963.
Dinse, H., Speichert, L. J., Schweda, A., Witzke, O., Konik, M., Zettler, M., Rohn, H., Stettner, M., Musche, V., Weismüller, B., Herchert, K., Fink, M., Moradian, S., Teufel, M., Skoda, E. M., & Bäuerle, A. (2022). Comment on Schäfer et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence": High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence. Psychotherapy and psychosomatics, 1-3. https://doi.org/10.1159/000520963
Dinse, Hannah, et al. "Comment on Schäfer et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence": High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence." Psychotherapy and psychosomatics vol. (2022): 1-3. doi: https://doi.org/10.1159/000520963
Dinse H, Speichert LJ, Schweda A, Witzke O, Konik M, Zettler M, Rohn H, Stettner M, Musche V, Weismüller B, Herchert K, Fink M, Moradian S, Teufel M, Skoda EM, Bäuerle A. Comment on Schäfer et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence": High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence. Psychother Psychosom. 2022 Jan 05;1-3. doi: 10.1159/000520963. Epub 2022 Jan 05. PMID: 34986479.
Copy Download .nbib Format: NLM
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders.

Cancer discovery

Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB.
PMID: 34635570
Cancer Discov. 2021 Oct 11; doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11.

Personalized medicine aims to match the right drug with the right patient by utilizing specific features of the individual patients' tumor. However, current strategies of personalized therapy matching only provide treatment opportunities for less than 10% of cancer patients....

Cite
Kornauth C, Pemovska T, Vladimer GI, et al. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-0538.
Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., Felsleitner-Hauer, V., Forte, M., Gaiger, A., Geissler, K., Greinix, H. T., Gstöttner, W., Hacker, M., Hartmann, B. L., Hauswirth, A. W., Heinemann, T., Heintel, D., Hoda, M. A., Hopfinger, G., Jaeger, U., Kazianka, L., Kenner, L., Kiesewetter, B., Krall, N., Krajnik, G., Kubicek, S., Le, T., Lubowitzki, S., Mayerhoefer, M. E., Menschel, E., Merkel, O., Miura, K., Müllauer, L., Neumeister, P., Noesslinger, T., Ocko, K., Öhler, L., Panny, M., Pichler, A., Porpaczy, E., Prager, G. W., Raderer, M., Ristl, R., Ruckser, R., Salamon, J., Schiefer, A. I., Schmolke, A. S., Schwarzinger, I., Selzer, E., Sillaber, C., Skrabs, C., Sperr, W. R., Srndic, I., Thalhammer, R., Valent, P., van der Kouwe, E., Vanura, K., Vogt, S., Waldstein, C., Wolf, D., Zielinski, C. C., Zojer, N., Simonitsch-Klupp, I., Superti-Furga, G., Snijder, B., & Staber, P. B. (2021). Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-0538
Kornauth, Christoph, et al. "Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-0538
Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. Cancer Discov. 2021 Oct 11; doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11. PMID: 34635570.
Copy Download .nbib Format: NLM
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Cancer discovery

Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB.
PMID: 34635570
Cancer Discov. 2021 Oct 11; doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11.

Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer....

Cite
Kornauth C, Pemovska T, Vladimer GI, et al. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-0538.
Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., Felsleitner-Hauer, V., Forte, M., Gaiger, A., Geissler, K., Greinix, H. T., Gstöttner, W., Hacker, M., Hartmann, B. L., Hauswirth, A. W., Heinemann, T., Heintel, D., Hoda, M. A., Hopfinger, G., Jaeger, U., Kazianka, L., Kenner, L., Kiesewetter, B., Krall, N., Krajnik, G., Kubicek, S., Le, T., Lubowitzki, S., Mayerhoefer, M. E., Menschel, E., Merkel, O., Miura, K., Müllauer, L., Neumeister, P., Noesslinger, T., Ocko, K., Öhler, L., Panny, M., Pichler, A., Porpaczy, E., Prager, G. W., Raderer, M., Ristl, R., Ruckser, R., Salamon, J., Schiefer, A. I., Schmolke, A. S., Schwarzinger, I., Selzer, E., Sillaber, C., Skrabs, C., Sperr, W. R., Srndic, I., Thalhammer, R., Valent, P., van der Kouwe, E., Vanura, K., Vogt, S., Waldstein, C., Wolf, D., Zielinski, C. C., Zojer, N., Simonitsch-Klupp, I., Superti-Furga, G., Snijder, B., & Staber, P. B. (2021). Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-0538
Kornauth, Christoph, et al. "Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-0538
Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discov. 2021 Oct 11; doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11. PMID: 34635570.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries